Track topics on Twitter Track topics that are important to you
Rixathon, a biosimilar to rituximab and manufactured by Sandoz, was approved in Europe for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, according to a company press release.“Today’s approval of Rixathon represents a big win for patients in Europe with blood cancers and immunological diseases because it enables increased access to biologics,” Carol Lynch, global head of biopharmaceuticals at Sandoz, said in the release. “It also allows health care systems to redeploy resources to other areas of high need, particularly innovative therapies.”
Original Article: Biosimilar to rituximab approved in EuropeNEXT ARTICLE
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...